iShares Biotechnology ETF
670 hedge funds and large institutions have $5.57B invested in iShares Biotechnology ETF in 2019 Q1 according to their latest regulatory filings, with 98 funds opening new positions, 189 increasing their positions, 237 reducing their positions, and 67 closing their positions.
46% more first-time investments, than exits
New positions opened: 98 | Existing positions closed: 67
21% more capital invested
Capital invested by funds: $4.61B → $5.57B (+$960M)
6.33% more ownership
Funds ownership: 61.99% → 68.32% (+6.3%)
3% more funds holding
Funds holding: 649 → 670 (+21)
17% less funds holding in top 10
Funds holding in top 10: 18 → 15 (-3)
20% less repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 237
32% less call options, than puts
Call options by funds: $392M | Put options by funds: $579M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$186M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$149M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$93.8M |
| 4 |
Citigroup
New York
|
+$81.1M |
| 5 |
DFO
Duquesne Family Office
New York
|
+$48.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$67.3M |
| 2 |
Millennium Management
New York
|
-$51.7M |
| 3 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$46.4M |
| 4 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
-$40.7M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$33M |
IBB Hedge Fund Activity: Q1 2019 in Review
670 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2019, worth a combined $5.57B — up 21% from $4.61B a quarter earlier.
Buyers outnumbered sellers: 98 funds opened new IBB positions and 67 closed out — a net gain of 31 holders — while 189 added to existing stakes and 237 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $186M. The largest seller was JP Morgan Chase, cutting an estimated $67.3M.
- 670 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2019, up from 649 in Q4 2018.
- Funds reported $5.57B of iShares Biotechnology ETF stock for Q1 2019, up 21% quarter-over-quarter.
- 98 funds opened new iShares Biotechnology ETF positions in Q1 2019 and 67 closed out, a net change of +31 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2019 was Goldman Sachs, an estimated $186M added.
- The largest iShares Biotechnology ETF seller in Q1 2019 was JP Morgan Chase, an estimated $67.3M sold.
Based on aggregated 13F filings for Q1 2019.